Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avocadene SCHEMBL1051284 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadene SCHEMBL15944388 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadyne SCHEMBL18730915 | 0.87 | USP2 (1.00) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31619136 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadyne SCHEMBL1970908 | 0.87 | USP2 (1.00) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30697474 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadene SCHEMBL15191342 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31619135 | 0.87 | USP2 (0.76) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadyne Acetate SCHEMBL25216029 | 0.79 | USP2 (1.00) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 | |
| Avocadyne SCHEMBL30697473 | 0.78 | USP2 (0.81) | USP2CYP3A4SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390423-B2 | Avocatin B for the treatment of diseases and conditions | SP NUTRACEUTICALS INC. (CA) | 2025-08-19 | — | — | US | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | LUNELLA BIOTECH, INC. (CA) | 2023-06-13 | — | — | US | claimed |
| US-20230140688-A1 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | SP NUTRACEUTICALS INC. (CA) | 2023-05-04 | — | — | US | claimed |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH, INC. (CA) | 2022-06-30 | — | — | US | claimed |
| EP-3976197-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | Lunella Biotech, Inc. (CA) | 2022-04-06 | — | — | EP | claimed |
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | LUNELLA BIOTECH, INC. (CA) | 2026-02-17 | — | — | US | disclosed |
| EP-4620479-A1 | POSTBIOTIC PREPARATION COMPRISING PEDIOCOCCUS ACIDILACTICI FOR PREVENTING OR TREATING OBESITY | Genbioma Aplicaciones, S.L. (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-12390423-B2 | Avocatin B for the treatment of diseases and conditions | SP NUTRACEUTICALS INC. (CA) | 2025-08-19 | — | — | US | disclosed |
| US-12390423-B2 | Avocatin B for the treatment of diseases and conditions | SP NUTRACEUTICALS INC. (CA) | 2025-08-19 | — | — | US | disclosed |
| US-12390423-B2 | Avocatin B for the treatment of diseases and conditions | SP NUTRACEUTICALS INC. (CA) | 2025-08-19 | — | — | US | disclosed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | disclosed |
| US-20250114413-A1 | SYNBIOTIC SUPPLEMENT FORMULATION | MEDISYN BIO INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20230140688-A1 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | SP NUTRACEUTICALS INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| EP-4168006-A1 | NEW STRATEGY FOR TREATING PANCREATIC CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-26 | — | — | EP | disclosed |
| US-20230040965-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | LUNELLA BIOTECH, INC. (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230038352-A1 | PROBIOTICS FOR REGULATING BLOOD GLUCOSE | GENBIOMA APLICACIONES, S.L. (ES) | 2023-02-09 | — | — | US | disclosed |
| US-11497759-B2 | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells | LUNELLA BIOTECH, INC. (CA) | 2022-11-15 | — | — | US | disclosed |
| EP-4076484-A1 | PROBIOTICS FOR REGULATING BLOOD GLUCOSE | Genbioma Aplicaciones, S.L. (ES) | 2022-10-26 | — | — | EP | disclosed |
| US-11441195-B2 | Energetic cancer stem cells (e-CSCs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | LUNELLA BIOTECH, INC. (CA) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | CYP27B1, TFAM, FIS1 | USP2 1052/4885CYP3A4 1140/4885SMN1; SMN2 1917/4885 |
| US-12553092-B2 | Energetic cancer stem cells (E-CSCS): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | TXNRD2, TXNRD1, TXN2 | USP2 1958/4885CYP3A4 2368/4885SMN1; SMN2 3477/4885 |
| US-11441195-B2 | Energetic cancer stem cells (e-CSCs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy | ALDH2, ALDH5A1, ECHS1 | USP2 2037/4885CYP3A4 2819/4885SMN1; SMN2 4190/4885 |
| US-20230040965-A1 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | ALDH2, ECHS1, ALDH5A1 | USP2 1643/4885CYP3A4 3506/4885SMN1; SMN2 4459/4885 |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | CYP27B1, TFAM, FIS1 | USP2 1052/4885CYP3A4 1140/4885SMN1; SMN2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.